progression among medication users in the Osteoarthritis Initiative (OAI) to identify interventions or pathways that may be of interest for future clinical trials. Methods: An exploratory analysis was conducted using OAI participants with annual medication inventory form data between baseline and the 36-month (mo) follow-up visit (n ¼ 2,938). Consistent medication users were defined for each medication classification (class) as a participant reporting at every annual visit that they were regularly using an oral prescription medication at the time of the clinic visit. Two definitions of consistent medication nonuser were assessed: 1) definite nonuser: participants never reported the prescription medication, and 2) probable nonuser: participants never reported regularly using an oral prescription medication at the time of the clinic visit. The exploratory analysis focused on medication classes with ! 40 users. Key outcome measures were 12-mo quantitative joint space width at x ¼ 0.250 (JSW250), JSW250 change (12-mo to 36-mo visits), 12-mo WOMAC pain score, and WOMAC pain score change (12-mo to 36-mo visits). Change was calculated as follow-up minus baseline. Each medication class was analyzed separately. We explored five sets of comparisons including three with nonusers matched to users based on OAI cohort, race, gender, age (AE 5 years), and body mass index (AE 5 kg/m 2 ): 1) no matching: users to all definite nonusers, 2) matched: users to definite nonusers, 3) matched and restricted to only participants with JSW250 data: users to definite nonusers, 4) no matching: users to all probable nonusers, and 5) matched: users to probable nonusers. A Cohen effect size was generated for each medication class in each set of comparisons (d¼ [user mean-nonuser mean] divided by pooled standard deviation). Medication classes with 4 out of 5 effect sizes for JSW250 change > 0.10 or < -0.10 for WOMAC pain change were further explored with box plots to determine if the median change of matched definite nonusers was beyond interquartile range (IQR) of users.
Results: Twenty-six medication classes were eligible for screening (Table  1) . Table 1 contains sample sizes and effect sizes for each medication class. Anti-estrogen, anticonvulsants, antineoplastic agents, progestogens, antidepressants, hypoglycemics, and ACE inhibitors were further explored with box plots for JSW250 change. Anti-estrogen users' IQR included less JSW250 change than the median for nonusers. Progestogens also had a potential signal but the other medications had clear overlap between users and nonusers. For symptom modification, alpha-adrenergic blockers and diuretics were further explored with box plots of WOMAC pain change. Alpha-adrenergic users' IQR included greater improvement in WOMAC pain scores than the median for nonusers but diuretic users and nonusers had clear overlap.
Conclusions: A hormonal pathway, theoretically associated with bone turnover, may be an area for further focus since anti-estrogen and progestogen users had evidence of slower JSW change while bisphosphonate users had greater JSW change. Furthermore, weak but consistent evidence suggested that central nervous system agents may deserve further research since anticonvulsants and antidepressant users had slower JSW change while anxiolytics users had greater JSW change. with Kellgren-Lawrence Grades 1 and 2 OA, and who never had prior VS or knee surgery, were scanned at baseline, 6 weeks post-, and 3 months post-VS using Hylan G-F 20 (3T, Siemens Medical Solutions, Malvern, PA). T1-weighted isotropic MPRAGE images were acquired for segmentation of cartilage, and T1r-weighted 3D TrueFISP images were acquired to calculate spatial T1r relaxation maps. Sixteen T1r-weighted slices were acquired in each aspect to allow for volumetric analysis. Image acquisition parameters have been described previously. Isotropic sagittal MPRAGE images were re-sliced along coronal and axial views and interpolated to match the resolution of T1r-weighted images. Inter-and intra-scan motion was corrected 3D rigid-body co-registration algorithms (Analyze, AnalyzeDirect, Inc., KS). Femoral and tibial images were co-registered separately due to discrepancies in flexion angle between imaging sessions. ROI analysis was performed on the same locations for three time points to accurately quantify changes in T1r through mean compartmental analysis and percent change maps from baseline images. Cartilage was segmented using the SliceOMatic (Tomovision, Quebec, CA) software package. Coregistered T1r-weighted images were fit pixelwise to the linearized, mono-exponential signal decay equation ln(S) ¼ -TSL/T1r + ln(S0). Volumetric T1r means were calculated by layer depth (superficial, middle, deep) as well as by region (medial and lateral patella, femoral condyles, and tibial plateau). Statistical analysis was performed using a one-tailed paired t-test between time points. Additional data to be analyzed but not present for this abstract include the visual analog pain, WOMAC, and IKDC subjective scores before injection and at the time of follow-up MRI. WORMS scoring for each patient is currently being performed and will be correlated to quantitative findings. Statistical significance was accepted when p<0.05. There were significant differences in volumetric T1r scores in both the medial and lateral compartments of the superficial patella (p< 0.05) 6 weeks following but not after three months (Med. -p<0.1, Lat. -p 20% across the entire patella while Figure 2 has no significant difference in average between two following time points. There is a large region across the middle of the lateral facet with an average T1r score < 20% versus the volumetric mean. This trend of non-uniform spatial changes to T1r following VS regiments is prevalent among all patients. Conclusions: These data suggest that VS has a quantifiable physiological effect on knee articular cartilage. This effect is greater in the superficial layers than in the deep layers. Intuitively, direct contact between VS and cartilage occurs at the superficial layer, and there may be a subsequent physical mechanism of action for VS. Interestingly, the greatest effects were observed in the patella-femoral compartment which may be due to lower load-bearing activities and increased cartilage thickness. Future work will assess methods to predict homoor heterogeneous changes within the articular cartilage through correlation analysis with WORMS, WOMAC, and other qualitative assessments. While some patients responded positively to the VS, as calculated through lower T1r scores, there were some who did not or had higher T1r values. There may be both placebo effects as well as anti-inflammatory mechanisms associated with the VS which allowed patients to push through pain more than before thereby causing increased damage to the cartilage tissue.
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